First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

NCT05921929 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped a new trial should be designed

Conditions

PTSD
Alzheimer Disease
Brain Diseases
Neuro-Degenerative Disease
Major Depressive Disorder
Treatment Resistant Depression

Interventions

DRUG: Fluoroethylnormemantine (FENM)

Sponsor

ReST Therapeutics